AZD1152 in Patients With Advanced Solid Malignancies-Study 1

AstraZeneca

Status and phase: Terminated; Phase 1

Conditions: Solid Tumors

Treatments: Drug: AZD1152

Study type: Interventional

Funder types: Industry

Identifiers

NCT00497731

D1531C00001

Details and patient eligibility

About

The primary purpose of this protocol is to investigate the safety and tolerability of AZD1152 when given as a continuous 2-hour infusion every week and every 2 weeks in patients with advanced solid malignancies.

Enrollment: 70 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Histological or cytological confirmation of a solid, malignant tumour
• At least measurable or non measurable site of disease as defined by modified RECIST criteria.

Exclusion criteria

• Participation in an investigational drug study within 30 days prior to entry or who have not recovered from the effects of an investigational study drug
• Treatment with radiotherapy/chemotherapy with 4 weeks of first dose
• Recent major surgery within 4 weeks prior to entry to the study

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)